Global Biologics Market - Analysis and Forecast (2017-2025)

(Focus on Pipeline Analysis, Product Type, Therapeutic Application, Country Analysis, and Market Dynamics)

Published Year: 2017
SKU: BH00490SA

4599

Online Access for One Person. Permission to Print

A quick peek into the report

Table of Contents

Request a Sample

Report Scope and Methodology

1.1. Scope of the Report
1.2. Global Biologics Market Segmentation 
1.3. Key Learnings 
1.4. Research Methodology
1.4.1.  Key Data Points From Secondary Sources 
1.4.2.  Key Data Points From Primary Sources 
1.4.3.  Top-Down Approach (Segmental Analysis)
1.4.4.  Bottom-Up Approach (Segmental Analysis)
1.4.5.  Assumption and Limitations 
1.4.6.  Data and Prediction Modelling 

Market Overview

2.1. Introduction
2.2. Market Dynamics
2.2.1.  Market Drivers
2.2.2.  Market Restraints
2.2.3.  Market Opportunities

Global Biologics Market by Therapeutics

3.1. Overview
3.2. Market Trend Analysis
3.3. Oncology
3.4. Cardiovascular
3.5. Immunological Diseases
3.6. Infectious Diseases
3.7.  Metabolic Diseases

Global Biologics Market by Product

4.1. Overview
4.2. Market Trend Analysis
4.3. Monoclonal Antibodies (mAbs)
4.4. Hormones
4.5. Growth Factors
4.6. Fusion Proteins
4.7. Cytokines
4.8. Therapeutic Enzymes
4.9. Blood Factors and Anticoagulants
4.10.  Vaccines

Global Biologics Market by Geography

5.1. Overview
5.2. North America
5.2.1.  The U.S.
5.2.2.  Canada
5.3. Europe
5.3.1.  Germany
5.3.2.  France
5.3.3.  The U.K.
5.3.4.  Italy
5.3.5.  Spain
5.4. Asia Pacific (APAC)
5.4.1.  Japan
5.4.2.  China
5.4.3.  Australia
5.4.4.  India
5.5. Latin America
5.6. Middle East Africa
5.7. Rest of the World (RoW)

Competitive Landscape

6.1. Key Developments and Strategies
6.2. Regulatory Body Clearance
6.3. New Product Launches and Developments
6.4. Merger & Acquisitions
6.5. Agreements, Joint Ventures and Partnerships
6.6. Business Expansion
6.7. Others
6.8. Patent Landscape

Company Profiles

7.1. AbbVie Inc.
7.2. Allergan Plc 
7.3. Amgen Inc.
7.4. Astellas Pharma Inc.
7.5. AstraZeneca PLC
7.6. Bayer AG
7.7. Biocon Ltd.
7.8. Boehringer Ingelheim GmbH
7.9. Bristol-Myers Squibb Company
7.10.  Eli Lilly and Company
7.11. F. Hoffmann-La Roche AG 
7.12.  Gilead Sciences, Inc.
7.13.  GlaxoSmithKline Plc
7.14.  Johnson & Johnson
7.15.  Merck & CO., Inc.
7.16.  Merck KGaA
7.17.  Novartis AG
7.18.  Novo Nordisk
7.19.  Pfizer Inc.
7.20.  Sanofi
7.21.  Teva Pharmaceuticals Industries Limited

List of Tables

1 Regulatory Types of Biological Products
2 Pharmaceutical Spending Trends
3 Global Pharmaceutical Product Rank by Sales (Conventional and Biologics)
4 Biosimilar Products Approved by the EMA as of May, 22, 2017
5 Biosimilar Products Approval Pathway in the U.S. (as of May, 22, 2017)
6 351(k) Applications Under First-Cycle Review
7 Top Selling mAbs, 2016
8 Biosimilars in Development by Chinese Companies
9 Global Biologics Drug Discovery Market by Therapeutic Area, 2014-2025
10 Biologics & Indications (Oncology)
11 Biologics & Indications (Cardiovascular Disease)
12 Biologics & Indications (Immunological Disorder)
13 Biologics & Indications (Infectious disease)
14 Biologics & Indications (Metabolics)
15 Biologics & Indications (Hematology)
16 Global Biopharmaceuticals Market Size, by Region 2014-2025, ($Billion)
17 Regulatory Body Clearance
18 New Product Launches and Developments
19 Merger & Acquisitions
20 Agreements, Joint Ventures and Partnerships
21 Business Expansion
22 Awards, Certifications and Other Developments
23 Patents Granted to Companies
24 Overview: AbbVie Inc.
25 Overview: Allergan Plc
26 Overview: Amgen Inc.
27 Overview: Astellas Pharma Inc. 
28 Overview: AstraZeneca PLC
29 Overview : Bayer AG
30 Overview : Biocon Ltd.
31 Overview : Boehringer Ingelheim GmbH
32 Overview : BRISTOL-MYERS SQUIBB COMPANY
33 Overview : Eli Lilly and Company
34 Overview : Hoffmann-La Roche AG 
35 Overview : GILEAD SCIENCES, INC.
36 Overview : GlaxoSmithKline Plc
37 Overview : JOHNSON & JOHNSON
38 Overview : Merck & CO., Inc.
39 Overview : Merck KGaA
40 Overview : Novartis AG
41 Overview : NOVO NORDISK
42 Overview : Pfizer Inc.
43 Overview : Sanofi
44 Overview : Teva Pharmaceuticals Industries Limited.

List of Tables

1 Approval Pathways for Small-Molecule Drugs
2 Global Pharmaceutical Sales (Conventional Vs Biologics), ($Billion)
3 Global Pharmaceutical Sales (Conventional Vs Biologics) % share ($Billion)
4 Top Pharmaceutical Market 
5 Top Biologics Market 
6 Global Biologic Drug Sales ($Billion)
7 Growth Rate: Patented Biologics Vs Biosimilars
8 Market Revenue: Patented Biologics Vs Biosimilars ($Billion) 
9 Biologic Molecule Scenarios in the U.S. after Biosimilar Introduction
10 Global Biologics Drugs Market by Class, ($Billion)
11 Global Biologic Drugs Market , 2016
12 Global Biologic Drugs Market , 2025
13 Biologic Drugs by Indications, ($Billion)
14 Biologic Drugs by Indications, 2016
15 Biologic Drugs by Indications, 2025
16 Investigational Biologics by Indications
17 Global Biologic Drugs Market: Regional Prospective 
18 Global Biologic Drugs Demand, 2016
19 Global Biologic Drugs Market by Region, $Billion 
20 Global Biologic Drugs Market by Region, 2016
21 Global Biologic Drugs Market by Region, 2025
22 Research Methodology
23 Data Triangulation
24 Key Data Points From Secondary Sources 
25 Key Data Points From Primary Sources 
26 Top-Down  Approach (Segmental Analysis)
27 Bottom-Up Approach (Segmental Analysis)
28 Assumptions and Limitations
29 Clinical Trail Products Type Share by Therapeutic Areas
30 Global  Biologics  Market Size Therapeutic Areas,  2016 and 2025, ($Billion)
31 Global Oncology Biologics Products Market Size,  2014-2025, ($Billion)
32 Global Cardiovascular Biologics Products Market Size,  2014-2025, ($Billion)
33 Global Market Size of  Products for Immunological Diseases,  2014-2025 ($Billion)
34 Global Market Size of  Products for Infectious Diseases,  2014-2025 ($Billion)
35 Global Market Size of  Products for Metabolic Diseases,  2014-2025, ($Billion)
36 Global Market Size of  Products ,  2014-2025, ($Billion)
37 Different Types of Biologics or Biopharmaceuticals
38 Global Biopharmaceutical Market Size,  2014 and 2025, ($Billion)
39 Global mAbs Market Size,  2014 and 2025 ($Billion)
40 Market Size of Top mAbs Products,  2014 and 2025 ($Billion)
41 Global Hormones Market Size,  2014 and 2025 ($Billion)
42 Market Size of Top Hormone Products,  2014 and 2025 ($Billion)
43 Global Growth Factors Market Size,  2014 and 2025, ($Billion)
44 Market Size of Top Growth Factor Products,  2014 and 2025 ($Billion)
45 Global Fusion Proteins Market Size,  2014 and 2025 ($Billion)
46 Market Size of Top Fusion Protein Products,  2014 and 2025, ($Billion)
47 Global Cytokine Market Size,  2014 and 2025, ($Billion)
48 Market Size of Top Cytokine Products,  2014 and 2025 ($Billion)
49 Global Therapeutic Enzymes Market Size,  2014 and 2025, ($Billion)
50 Market Size of Top Therapeutic Enzyme Products,  2014 and 2025, ($Million)
51 Global Blood Factors and Anticoagulants Market Size,  2014 and 2025, ($Billion)
52 Market Size of Top Blood Factors and Anticoagulant Products,  2014 and 2025, ($Billion)
53 Global Vaccines Market Size,  2014 and 2025 ($Billion)
54 Market Size of Top Recombinant Vaccines,  2014 and 2025 ($Billion)
55 Global Scenario 
56 Figure: North America Biologic Market Size, 2014 and 2025 ($Billion)
57 Country Analysis, North America
58 Europe Biologics Market Size,  2014 and 2025, ($Billion)
59 Country Analysis, Europe
60 Asia Pacific Biologic Market Size,  2014 and 2025 ($Billion)
61 Country Analysis, Asia Pacific
62 Latin America Biologic Market Size,  2014 and 2025, ($Billion)
63 Country Analysis, Latin America
64 Share of Key Development and Strategies
65 Total Number of Strategies and Developments
66 AbbVie Inc.:Product Portfolio
67 Financials
68 AbbVie Inc.:  Net Sales by Geographic Destination (2014-2016)
69 AbbVie Inc. : SWOT Analysis
70 Allergan Plc: Product Portfolio
71 Financials
72 Allergan Plc: Net Sales by Business Segments (2015-2016)
73 Allergan Plc: Net Sales by Business Segment (2014)
74 Allergan Plc: SWOT Analysis
75 Amgen Inc.: Product Portfolio
76 Amgen Inc. : Overall Financials (2014-2016)
77 Amgen Inc. :  Net Sales by Geographic Destination (2014-2016)
78 Amgen Inc. : SWOT Analysis
79 Astellas Pharma Inc. : Overall Financials (2014-2016)
80 Astellas Pharma Inc. : Net Sales by Product Type (2014-2016)
81 Astellas Pharma Inc.  : Net Sales by Geographic Destination (2014-2016)
82 Astellas Pharma Inc. : SWOT Analysis
83 AstraZeneca PLC: Product Portfolio
84 AstraZeneca PLC : Overall Financials, 2014-2016
85 AstraZeneca PLC : Net Revenue by Business Segment, 2014-2016
86 AstraZeneca PLC : Revenue across Different Geographies, 2014-2016
87 AstraZeneca PLC: SWOT Analysis
88 Bayer AG: Product Portfolio
89 Bayer AG : Overall Financials, 2014-2016
90 Bayer AG : Net Revenue by Business Segment, 2014-2016
91 Bayer AG: Net Revenue by Geographic Destination, 2014-2016
92 Bayer AG: SWOT Analysis
93 Biocon Ltd.: Product Portfolio
94 Biocon Ltd. : Overall Financials, 2015-2017
95 Biocon Ltd.: Net Revenue by Business Segment, 2015-2017
96 Biocon Ltd. : Net Revenue by Pharma Business Segment, 2014-2016
97 Biocon Ltd. : Revenue across Different Geographies, 2014-2016
98 Biocon Ltd.: SWOT Analysis
99 Boehringer Ingelheim GmbH: Product Portfolio
100 Boehringer Ingelheim GmbH : Overall Financials (2014-2016)
101 Boehringer Ingelheim GmbH : Net Sales by Product Type (2014-2016)
102 Boehringer Ingelheim GmbH : Net Sales by Geographic Destination (2014-2016)
103 Boehringer Ingelheim GmbH: SWOT Analysis
104 BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio
105 BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2016)
106 BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Product Type (2014-2016)
107 BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Geographic Destination (2014-2016)
108 BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
109 Eli Lilly and Company: Product Portfolio
110 Eli Lilly and Company : Overall Financials (2014-2016)
111 Eli Lilly and Company : Net Sales by Product Type (2014-2016)
112 Eli Lilly and Company : Net Sales by Geographic Destination (2014-2016)
113 Eli Lilly and Company: SWOT Analysis
114 F. Hoffmann-La Roche AG : Product Portfolio
115 Roche AG: Overall Financials, (2013–2016)
116 Roche AG: Revenue across Different Geographies, (2013-2016)
117 Roche AG: Net Revenue by Business Segment, (2013-2016)
118 Roche AG: SWOT Analysis
119 GILEAD SCIENCES, INC.: Product Portfolio
120 GILEAD SCIENCES, INC. : Overall Financials (2014-2016)
121 GILEAD SCIENCES, INC. : Net Sales by Geographic Destination (2014-2016)
122 GILEAD SCIENCES, INC. : SWOT Analysis
123 GlaxoSmithKline Plc: Product Portfolio
124 GSK: Overall Financials (2013-2016)
125 GSK: Net Revenue by Business Segments (2013-2016)
126 GSK: Net Revenue by Geography (2013-2015)
127 GSK: Net Revenue by Geography (2016)
128 GlaxoSmithKline Plc: SWOT Analysis
129 JOHNSON & JOHNSON: Product Portfolio
130 JOHNSON & JOHNSON: Overall Financials (2014-2016) 
131 JOHNSON & JOHNSON : Net Revenue by Business Segment (2014-2016)
132 JOHNSON & JOHNSON : Net Revenue by Region (2014-2016)
133 JOHNSON & JOHNSON: SWOT Analysis
134 Merck & CO., Inc.: Product Portfolio
135 Merck & CO., Inc.: Overall Financials (2013-2016)
136 Merck & CO., Inc.: Net Revenue by Business Segments (2013-2014)
137 Merck & CO., Inc.: Net Revenue by Business Segments (2015-2016)
138 Merck & CO., Inc.: Net Revenue by Geography (2013-2014)
139 Merck & CO., Inc.: Net Revenue by Geography (2015-2016)
140 Merck & Co., Inc. : SWOT Analysis
141 Merck & CO., Inc. KGaA: Overall Financials, (2014-2016)
142 Merck & CO., Inc. KGaA: Net Revenue by Business Segments, (2014-2016)
143 Merck & CO., Inc. KGaA: Net Revenue by Geography, (2014)
144 Merck & CO., Inc. KGaA: Net Revenue by Geography, (2015-2016)
145 Merck KGaA : SWOT Analysis
146 Novartis AG: Product Portfolio
147 Novartis: Overall Financials (2013-2016)
148 Novartis: Net Revenue by Business Segments, (2013-2014)
149 Novartis: Net Revenue by Business Segments (2015-2016)
150 Novartis: Net Revenue by Geography  (2013-2016)
151 Novartis AG: SWOT Analysis
152 NOVO NORDISK: Product Portfolio
153 Novo Nordisk: Overall Financials, 2014-2016
154 Novo Nordisk: Net Revenue by Business Segment, 2014-2016
155 Novo Nordisk: Revenue across Different Geographies, 2014-2016
156 NOVO Nordisk: SWOT Analysis
157 Pfizer Inc.: Product Portfolio
158 Pfizer: Overall Financials (2013-2016)
159 Pfizer: Net Revenue by Geography (2013-2016)
160 Pfizer: Net Revenue by Business Segments (2013-2014)
161 Pfizer: Net Revenue by Business Segments (2015-2016)
162 Pfizer Inc. : SWOT Analysis
163 Sanofi: Product Portfolio
164 Sanofi: Overall Financials (2014-2016)
165 Sanofi: Net Sales by Business Segments (2014-2016)
166 Sanofi: Net Sales by Geographic Destination (2014-2016)
167 Sanofi: Net Sales by Franchise (2014-2016)
168 Safoni: SWOT Analysis
169 Teva Pharmaceuticals Industries Limited.: Product Portfolio
170 Teva Pharmaceutical Industries Limited: Overall Financials, (2013-2016)
171 Teva Pharmaceutical Industries Limited : Net Revenue by Business Segments, (2013-2016)
172 Teva Pharmaceutical Industries Limited: Net Revenue by Geography, (2013-2016)
173 Teva Pharmaceutical Industries Ltd.: SWOT Analysis

Global Biologics Market - Analysis and Forecast (2017-2025)

(Focus on Pipeline Analysis, Product Type, Therapeutic Application, Country Analysis, and Market Dynamics)